Janice L Gabrilove, MD
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Oncological Sciences
Specialties:Cancer (Oncology), Hematology-Oncology
Research Topics:Bioinformatics, Biophysics, Computational Biology, Computer Simulation, Drug Design and Discovery, Integrins, Mathematical and Computational Biology, Membrane Proteins/Channels, Protein Complexes, Protein Structure/Function, Signal Transduction, Theoretical Biology, Theoretical Biophysics
Janice Gabrilove, MD, FACP, is The James F. Holland Professor of Medicine at the Icahn School of Medicine at Mount Sinai. She is the Director of the Clinical Research Education Program (Certificate, Master of Science, and PhD in Clinical Research) at the Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, and Co-Director of the Patient Oriented Research Training And Leadership (PORTAL) Program, a joint MD/Master of Science in Clinical Research Program. Dr. Gabrilove is also the Associate Director of Education and Training at The Tisch Cancer Institute.
Dr. Gabrilove is a world-renowned expert on the biology of hematopoietic growth factors in normal and malignant hematopoiesis and the role of these cytokines in ameliorating disease and treatment-related myelosuppression. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy-induced myelosuppression and severe chronic neutropenia. Her initial studies demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation revolutionized the way we perform stem cell transplantation today, utilizing G-CSF mobilized PBPC.
Dr. Gabrilove has been intimately involved in the development of novel therapeutics for fostering leukemic cell maturation, and received patents for two Food and Drug Administration (FDA) approved drugs for the treatment of Acute Promyelocytic Leukemia. She has served on the FDA Advisory Committee for the Approval of Biologics.
An elected member of the American Society for Clinical Investigation (ASCI), Dr. Gabrilove has received numerous awards in recognition of excellence in education, teaching and clinical care. Actively engaged in career development, she has mentored more than 38 residents, Hematology/Oncology fellows, and junior faculty.
American Board of Internal Medicine
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Biopsy
- Hematologic Malignancies
- Hodgkin's Disease
- Hodgkin's Lymphoma
- Myelodysplastic Syndromes
- Waldenström's Macroglobulinemia
MD, Mount Sinai School of Medicine
Residency, Internal Medicine, Columbia-Presbyterian Medical Ctr.
Fellowship, Hematology/Oncology, Memorial Sloan-Kettering
Role of Hematopoietic Factors in Normal Hematopoietic Cell Reconstitution
Dr. Gabrilove is a pioneer in the development of our understanding of the biology of hematopoietic growth factors and their clinical utility in promoting hematopoietic reconstitution. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy induced myelosuppression and severe chronic neutropenia. Her initial studies also demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation has revolutionized the way in which we perform marrow transplantation today, which is conducted almost exclusively utilizing G-CSF mobilized PBPC. This laboratory is currently investigating: